Compare · ARGX vs SNTI
ARGX vs SNTI
Side-by-side comparison of argenx SE (ARGX) and Senti Biosciences Inc. (SNTI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and SNTI operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $63.27B, about 5197.1x SNTI ($12.2M).
- Over the past year, ARGX is up 44.0% and SNTI is down 74.8% - ARGX leads by 118.8 points.
- ARGX has been more active in the news (11 items in the past 4 weeks vs 2 for SNTI).
- ARGX has more recent analyst coverage (25 ratings vs 3 for SNTI).
- Company
- argenx SE
- Senti Biosciences Inc.
- Price
- -
- -
- Market cap
- $63.27B
- $12.2M
- 1M return
- +14.62%
- +2.50%
- 1Y return
- +43.97%
- -74.79%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2021
- News (4w)
- 11
- 2
- Recent ratings
- 25
- 3
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- argenx downgraded by Deutsche Bank
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- SEC Form 6-K filed by argenx SE
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
- SEC Form SC TO-T filed by argenx SE
- Guggenheim resumed coverage on argenx with a new price target
- SEC Form 6-K filed by argenx SE
Latest SNTI
- SEC Form DEFA14A filed by Senti Biosciences Inc.
- Senti Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- SEC Form PREM14A filed by Senti Biosciences Inc.
- Amendment: SEC Form S-3/A filed by Senti Biosciences Inc.
- SEC Form DEFA14A filed by Senti Biosciences Inc.
- Senti Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Changes in Control of Registrant, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform
- The Radoff-JEC Group Releases Presentation Highlighting Why Seer, Inc. Stockholders Should Vote for Boardroom Change
- SEC Form S-3 filed by Senti Biosciences Inc.
- Senti Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits